151 related articles for article (PubMed ID: 34248112)
1. Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas.
Liu C; Nakano-Tateno T; Satou M; Chik C; Tateno T
Endocr J; 2021 Oct; 68(10):1143-1153. PubMed ID: 34248112
[TBL] [Abstract][Full Text] [Related]
2. BP-1-102 and silencing of Fascin-1 by RNA interference inhibits the proliferation of mouse pituitary adenoma AtT20 cells
Qian G; Xu J; Shen X; Wang Y; Zhao D; Qin X; You H; Liu Q
Int J Neurosci; 2021 Aug; 131(8):810-827. PubMed ID: 32326790
[TBL] [Abstract][Full Text] [Related]
3. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
4. Molecular Biology of Pituitary Adenomas.
Faltermeier CM; Magill ST; Blevins LS; Aghi MK
Neurosurg Clin N Am; 2019 Oct; 30(4):391-400. PubMed ID: 31471046
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between Expression of Signal Transducer and Activator of Transcription 3 and Pituitary Adenoma Subtypes].
Jiao YH; Liu XH; Dai CX; Cai F; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):693-7. PubMed ID: 26725392
[TBL] [Abstract][Full Text] [Related]
6. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas.
Feng J; Yu SY; Li CZ; Li ZY; Zhang YZ
Mol Cell Endocrinol; 2016 Nov; 436():195-203. PubMed ID: 27465831
[TBL] [Abstract][Full Text] [Related]
7. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
Grzywa TM; Klicka K; Rak B; Mehlich D; Garbicz F; Zieliński G; Maksymowicz M; Sajjad E; Włodarski PK
Endocrine; 2019 Sep; 65(3):646-655. PubMed ID: 31165412
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of growth-related factors in human pituitary adenomas. Lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas.
Otsuka F; Tamiya T; Yamauchi T; Ogura T; Ohmoto T; Makino H
Regul Pept; 1999 Aug; 83(1):31-8. PubMed ID: 10498342
[TBL] [Abstract][Full Text] [Related]
9. The Integrated Stress Response Is Tumorigenic and Constitutes a Therapeutic Liability in Somatotroph Adenomas.
Li Z; Chen Y; Yao X; Liu Q; Zhu H; Zhang Y; Feng J; Gao H
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361871
[TBL] [Abstract][Full Text] [Related]
10. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
Feng J; Hong L; Wu Y; Li C; Wan H; Li G; Sun Y; Yu S; Chittiboina P; Montgomery B; Zhuang Z; Zhang Y
J Neurooncol; 2014 Sep; 119(2):307-15. PubMed ID: 24916845
[TBL] [Abstract][Full Text] [Related]
11. Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools.
Yang Q; Wang Y; Zhang S; Tang J; Li F; Yin J; Li Y; Fu J; Li B; Luo Y; Xue W; Zhu F
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609812
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma.
Valiulyte I; Steponaitis G; Skiriute D; Tamasauskas A; Vaitkiene P
BMC Med Genet; 2017 Jul; 18(1):72. PubMed ID: 28709401
[TBL] [Abstract][Full Text] [Related]
13. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.
Hunter JA; Skelly RH; Aylwin SJ; Geddes JF; Evanson J; Besser GM; Monson JP; Burrin JM
Eur J Endocrinol; 2003 Feb; 148(2):203-11. PubMed ID: 12590639
[TBL] [Abstract][Full Text] [Related]
14. Follicle stimulating hormone-beta subunit gene is expressed in parallel with a transcription factor Ad4BP/SF-1 in human pituitary adenomas.
Ikuyama S; Ohe K; Sakai Y; Nakagaki H; Fukushima T; Kato Y; Morohashi K; Takayanagi R; Nawata H
Clin Endocrinol (Oxf); 1996 Aug; 45(2):187-93. PubMed ID: 8881451
[TBL] [Abstract][Full Text] [Related]
15. [Recent trends in the pathophysiology and treatment of pituitary adenomas].
Matsuno A
Brain Nerve; 2009 Aug; 61(8):957-62. PubMed ID: 19697885
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas.
Bamberger CM; Fehn M; Bamberger AM; Lüdecke DK; Beil FU; Saeger W; Schulte HM
Eur J Endocrinol; 1999 Mar; 140(3):250-5. PubMed ID: 10216521
[TBL] [Abstract][Full Text] [Related]
17. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway.
Miyakoshi T; Takei M; Kajiya H; Egashira N; Takekoshi S; Teramoto A; Osamura RY
Endocr Pathol; 2008; 19(4):261-73. PubMed ID: 19034702
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment.
Sanno N; Teramoto A; Osamura RY
J Neurooncol; 2001 Sep; 54(2):179-86. PubMed ID: 11761434
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
[TBL] [Abstract][Full Text] [Related]
20. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
